Novo Nordisk (NVO) shares declined 0.30% to $40.33, shedding $0.12 in the latest trading session after recovering from earlier lows. The dip came even as the pharmaceutical company pressed ahead with its DKK 15 billion share repurchase programme, which has now accumulated 41.7 million repurchased B shares.

Buyback Operates Under DKK 15 Billion Authorization

Novo Nordisk continued buying back its B shares under the repurchase programme launched on February 4, 2026, which permits the company to repurchase up to DKK 15 billion worth of shares over 12 months. The company also established a separate execution framework for purchases running from May 6, 2026, through February 1, 2027, under which it allocated up to DKK 11.2 billion for B-share repurchases. B shares are Novo Nordisk's publicly traded share class, and repurchase programmes of this kind are a standard mechanism through which listed companies return capital to shareholders.

The transactions are conducted under European market abuse regulations and the applicable safe harbour rules, which establish the regulatory framework governing share repurchases and the related market disclosures.

Six Sessions Add 1.44 Million Shares

The latest transaction update covers purchases completed between October 26 and November 2, 2026. Novo Nordisk bought 240,000 B shares on each reported trading day — October 26, 27, 28, 29, and 30, and November 2 — for a total of 1.44 million B shares across the six sessions. Average purchase prices ranged from DKK 257.51 to DKK 267.29 per share, adding approximately DKK 376 million to the programme's accumulated purchase value.

By day, the company paid an average of DKK 261.38 per share on October 26, DKK 260.44 on October 27, and DKK 257.51 on October 28. Average prices then rose to DKK 258.33 on October 29 and DKK 265.96 on October 30, and purchases resumed on November 2 at an average of DKK 267.29 per share, a session worth approximately DKK 64.15 million in total. Disclosures in this format give market participants a session-by-session record of how the authorization is being executed.

Following these purchases, cumulative transactions under the execution framework reached 26,955,000 B shares with a total value of DKK 7.76 billion.

Treasury Holdings Reach 55.7 Million Shares

Novo Nordisk reported holding 55,754,876 B shares as treasury shares after the latest purchases, representing approximately 1.2% of the company's total share capital. The company has 4.465 billion A and B shares outstanding, including treasury shares. Treasury shares are shares a company holds in its own name after buying them back, rather than shares held by outside investors, and because the reported holding exceeds the 41.7 million shares bought under the programme to date, the treasury position reflects repurchases accumulated over time rather than the current programme alone.

Programme 77.1% Complete

Since the overall programme began on February 4, 2026, Novo Nordisk had purchased 41,714,179 B shares by November 2, at an average price of DKK 277.23 per share. The total transaction value reached DKK 11,564,364,801, or approximately 77.1% of the DKK 15 billion allocation, meaning a significant portion of the authorized repurchase budget remains unused. That leaves roughly DKK 3.4 billion of the authorization outstanding, and all six of the latest session average prices came in below the programme-to-date average of DKK 277.23.

The company continues to execute the programme within its announced 12-month period, with its latest disclosures detailing transaction dates, purchased quantities, average prices, and cumulative values. With the 12-month window running to early February 2027 and roughly DKK 3.4 billion of the allocation unused, upcoming transaction notices will show the pace at which the remaining budget is deployed before the programme concludes. NVO shares nonetheless finished the latest session lower despite the ongoing repurchase activity.